Antibiotic susceptibility pattern and identification of extended spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae from Shiraz, Iran
,
Abstract
Background and Objectives: Klebsiella pneumoniae, one of the important causes of nosocomial infections, is the most common extended spectrum β-lactamases (ESBLs) producing organism. ESBLs are defined as the enzymes capable of hydrolyzing oxyimino-cephalosporins, monobactams and carbapenems. The aims of this study were to identify ESBL-producing K. pneumoniae isolates and detect their antibiotic susceptibility pattern.
Materials and Methods: This cross-sectional study was conducted from December 2012 to May 2013 in teaching hospitals in Shiraz. Clinical specimens from the urine, sputum, wound, blood, throat, and body fluids were isolated and identified as K. pneumoniae. Antibacterial susceptibility testing was performed for 14 antibiotics using disk diffusion method according to CLSI guidelines. Isolates showing resistant to at least one of the β-lactam antibiotics were then evaluated for production of β-lactamase enzymes using E-test ESBL and combined disk Method. Also, MICs for ceftazidime and imipenem were determined using E-test. The presence of the blaSHV, blaTEM٫ blaPER and blaCTX-M genes was assessed by PCR.
Results: Of 144 K. pneumoniae isolates from different specimens, 38 (26.3 %) was identified as ESBL producer by phenotypic confirmatory test. All ESBL producing isolates were susceptible to imipenem and meropenem and resistant to aztreonam. The highest rate of resistance belonged to amoxicillin (100%), cefotaxime (50%) and gentamicin (42.3%) and the lowest rates were seen for meropenem (11.8%), imipenem and amikacin (both 15.9%). Sixty-two isolates had MICs≥ 4 μg/ mL for ceftazidime, of which 38 were positive for ESBLs in phenotypic confirmatory tests (PCT). The prevalence of blaSHV, blaCTX-M, and blaTEM genes among these isolates were 22.2%, 19% and 16%. blaPER was not detected in the studied isolates.
Conclusions: Due to the relatively high prevalence of ESBLs-producing K. pneumoniae isolates in the studied population, it seems that screening of infections caused by ESBL producers can lead to the most effective antibiotics therapies.
Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE, Gaynes RP. Antimicrobial use and re- sistance in eight US hospitals: complexities of analysis and modeling. Intensive Care Antimicrobial Resis- tance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Con- trol Hosp Epidemiol 1998;19:388-394.
Podschun R, Ullmann U. Klebsiella spp. as nosocomi- al pathogens: epidemiology, taxonomy, typing meth- ods, and pathogenicity factors. Clin Microbiol Rev 1998;11:589-603.
Romanus II, Egwu OA, Ngozi AT, Chidiebube NA, Chika EP. Extended spectrum β –lactamase (ESBL) mediated resistance to antibiotics among Klebsiella pneumoniae in enugu Metropolis. Maced J Med Sci 2009;2:196-199.
Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
Knothe H, Shah PDP, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cef- amandole and cefuroxime in clinical isolates of Kleb- siella pneumoniae and Serratia marcescens. Infection 1983;11:315-317.
Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K.Novel plasmid-mediated β -lactamase (TEM-10) con- ferring selective resistance to ceftazidime and aztreo- nam in clinical isolates of Klebsiella pneumoniae. An- timicrob Agents Chemother 1989;33:1451-1456.
Rawat D, Nair D. Extended-spectrum β-lactamas-es in Gram negative bacteria. J Global Infect Dis.2010;2(3):263.
Eftekhar F, Naseh Z. Extended-spectrum β-lactamase and carbapenemase production among burn and non- burn clinical isolates of Klebsiella pneumoniae. Iran J Microbiol 2015;7:144.149.
Isaiah IN, Nche BT, Nwagu IG, Nwagu II. Incidence of temonera, sulphuhydryl variables and cefotaxi- mase genes associated with β-lactamase producing Escherichia coli in clinical isolates. N Am J Med Sci 2011;3:557-561.
Eftekhar F, Rastegar M, Golalipoor M, Mansoursa- maei N. Detection of extended spectrum β-Lactamases in urinary isolates of Klebsiella pneumoniae in relation to bla , bla TEM and bla CTX-M gene carriage. Iran J Pub- lic Health 2012;41:127-32.
Gales AC, Reis AO, Jones RN. Contemporary assess- ment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available inter- pretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-190.
Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012;67:622-632.
Paterson DL. Resistance in Gram-negative bacte-ria: Enterobacteriaceae. Am J Med 2006;119(6 Suppl 1):S20-8.
Nathisuwan S, Burgess DS, Lewis JS. Extended-spec- trum β-Lactamases: epidemiology, detection, and treatment. pharmacotherapy: Pharmacotherapy 2001;21:920-928.
Feizabadi MM, Etemadi G, Yadegarinia D, Rahma- ti M, Shabanpoor S, Bokaei S. Antibiotic-resistance patterns and frequency of extended-spectrum b-lact- amase-producing isolates of Klebsiella pneumoniae in Tehran. Med Sci Monit 2006;12(11):BR362-BR5.
Aminzadeh Z, Kashi MS, Shabani M. Bacteriuria by extended-spectrum β-lactamase-producing escherich- ia coli and Klebsiella pneumoniae. Iran J Kidney Dis 2008;2:197-200.
Ramazanzadeh R, Chitsaz M, Bahmani N. Prevalence and antimicrobial susceptibility of extended-spectrum β -lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran). Che- motherapy 2009;55:287-292.
Bazzaz BS NM, Mohamadpoor AH, Farshadzadeh Z, Ahmadi S, Yousefi F. The prevalence of extend- ed-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiol Immu- nol Hung 2009;56:89-99.
Mohanty S, Gaind R, Ranjan R, Deb M. Use of the cefepime-clavulanate ESBL Etest for detection of ex- tended-spectrum β -lactamases in AmpC co-producing bacteria. J Infect Dev Ctries 2009;4:24-29.
Walsh C. Natural and producer immunity versus ac- quired resistance. Antibiotics: actions, origins, resis- tance ASM Press, Washington DC, USA. 2003:91-105.
Leila N, Fereshteh S, Nikbin VS, Shoeib N. PER, CTX-M, TEM and SHV β -lactamases in clinical iso- lates of Klebsiella pneumoniae isolated from Tehran, Iran. Iran J Basic Med Sci 2010; 13:111-118.
Bush K. Extended-spectrum β-lactamases in North America, 1987–2006. Clin Microbiol Infect 2008;14(s1):134-43.
| Files | ||
| Issue | Vol 8 No 1 (2016) | |
| Section | Articles | |
| Keywords | ||
| Klebsiella pneumoniaee extended spectrum beta-lactamase Polymerase Chain Reaction E-test ESBL Combination disc | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
